Janssen touts Transposagen technology in CAR-T collaboration
This article was originally published in Scrip
Executive Summary
Transposagen Biopharmaceuticals doesn't make a big public fuss about its pharmaceutical collaborations – the Lexington, Kentucky-based company has relationships with 19 out of the top 20 big pharma – but the Johnson & Johnson subsidiary Janssen Biotech is happy to tout the promise of its new partner's technology.
You may also be interested in...
Gilead Partners With Sangamo For Gene Editing As It Builds Up Kite's Cell Therapy Platform
Gilead committed more than $3bn via its subsidiary Kite to license Sangamo's zinc finger technology for gene editing that may deliver improved T cell therapies for cancer. More deals are expected in this space as Gilead builds its cell therapy platform after buying Kite last year.
Finance Watch: Pfizer Adds $3.5bn To Cash Stockpile, Reduces Stake In Haleon
Public Company Edition: Pfizer’s stake in Haleon dropped from 32% to 22.6% with a massive sale of shares of the GSK consumer health spinout. Also, Galderma prices its Swiss IPO, Madrigal grosses $600m in a post-approval offering and bluebird secured up to $175m in debt.
Finance Watch: Another Bevy Of VC Mega-Rounds, Including $175m For Capstan
Private Company Edition: Capstan and Engrail raised $175m and $157m, respectively, in series B venture capital rounds in addition to Madrigal’s $400m-plus launch and Clasp’s $150m series A.